

## Board Meeting in Public

Tuesday, 26 March 2024

<b>Title of Report</b>	Care Quality Commission (CQC) Action Plan Report	<b>Agenda No.</b>	3.3
<b>Nature of Report</b> (tick one)	<input checked="" type="checkbox"/> Official	<input type="checkbox"/> Official Sensitive	
<b>Author(s)</b>	Iroro Agba, Assistant Director of Quality		
<b>Lead Executive</b>	Helen Gillan, Director of Quality		
<b>Non-Executive Director Sponsor</b> (if applicable)	N/A		
<b>Presented for</b> (tick all that applies)	<input type="checkbox"/> Approval	<input checked="" type="checkbox"/> Information	
	<input checked="" type="checkbox"/> Assurance	<input checked="" type="checkbox"/> Update	
<b>Purpose of the report and key issues</b>			
<p>The purpose of this paper is to provide an update and assurance to the Board on NHSBT's progress against its CQC action plan, following the Well-Led and regulated activity inspections in June &amp; August 2022.</p> <p>NHSBT created a robust response to the CQC findings. This included:</p> <ul style="list-style-type: none"> <li>- 33 actions for 6 MUST findings (organisational-wide).</li> <li>- 27 actions for 7 SHOULD findings (organisational-wide).</li> <li>- 23 actions for 5 SHOULD findings in Blood Donation (BD) and;</li> <li>- 26 actions for 5 SHOULD findings in Therapeutic Apheresis Service (TAS).</li> </ul> <p>Since the last update to the Board in January 2024, the final action on the Well Led Action Plan is complete:</p> <p>Audit of all Board-level committee structure to ensure effectiveness and appropriate reporting to the Board. (Action S6d on tracker attached).</p> <p>The effectiveness reviews of Board committees have been completed, action plans are being prepared and will be managed by the Company Secretary for the respective Board-level committees.</p> <p>All actions in response to the CQC report have been closed by NHSBT. An independent effectiveness review and evidence mapping was performed as part of this closure report, there were no gaps identified. As such, this report will cease to be presented to the Board beyond March 2024.</p> <p>However, a review of the fundamental standards and the associating quality statements continues across all our regulated activities and governance to enable NHSBT to maintain safety and inspection-readiness status.</p> <p>Dee Thiruchelvam is now the Nominated Individual for the CQC.</p>			

## Blood and Transplant

Previously Considered by	
N/A.	
Recommendation	<p>The Board is asked to:</p> <ol style="list-style-type: none"> <li>1) Note the closure of the action S6.</li> <li>2) Acknowledge the commitment shown by the organisation in completing all actions, thus, bringing to closure this improvement plan.</li> </ol>
Risk(s) identified (Link to Board Assurance Framework Risks)	
BAF 09: Regulatory risk	
Strategic Objective(s) this paper relates to: [Click on all that applies]	
<input type="checkbox"/> Collaborate with partners <input checked="" type="checkbox"/> Invest in people and culture <input type="checkbox"/> Drive innovation <input checked="" type="checkbox"/> Modernise our operations <input type="checkbox"/> Grow and diversify our donor base	
Appendices:	<p>CQC Report Action Plans</p> <ol style="list-style-type: none"> <li>1. Well Led Action Plan</li> </ol>